{
    "info": {
        "nct_id": "NCT05755087",
        "official_title": "Phase Ib Trial of Tegavivint in Patients with Relapsed/Refractory C-MYC Overexpressing Large B-Cell Lymphoma",
        "inclusion_criteria": "One of the following three conditions:\n\n* Relapsed/refractory histologically confirmed germinal center B-cell-like (GCB) and non-GCB diffuse large B cell lymphoma (DLBCL) with the following features:\n\n  * Increased expression of MYC (>= 40%) and BCL2 (>= 50%) by immunohistochemistry (IHC) or\n  * Presence of isolated MYC translocation Or\n* Relapsed/refractory histologically confirmed high-grade B-cell lymphoma (HGBCL) (double hit [DH] and triple hit [TH]) with translocations of MYC and BCL2 and/or BCL6 Or\n* Histologic transformation of indolent non-Hodgkin's lymphoma (NHL) to DLBCL\n\n  * Presence of BCL2 translocation with increased expression of MYC (≥40%) with or without MYC translocation\n* Patients must have had at least two prior systemic therapies\n* Patients must be ineligible for or refused autologous or allogenic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy. Prior autologous stem cell transplant and/or CAR-T are allowed, if received >= 3 months prior to enrollment\n* Age >= 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Patients must have radiographically measurable disease by standard positron emission tomography (PET) uptake with at least one site of measured disease by standardized uptake value (SUV)\n* Absolute neutrophil count (ANC) ≥ 500/mcL\n* Platelet count ≥ 25,000/mcL\n* Total bilirubin =< 1.5 x the upper limit of the normal range (ULN)\n* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x institutional ULN\n* Creatinine clearance >= 60 ml/min by Cockcroft-Gault (actual body weight will be used to estimate creatinine clearance)\n* Patients must be willing and able to understand and give written informed consent and comply with all study related procedures\n* Women of child-bearing potential (WOCBP) and men who are sexually active with WOCBP must agree to use one hormonal contraceptive (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy or tubal ligation; and one effective method of contraception, including male condom, female condom, cervical cap, diaphragm or contraceptive sponge or abstain from sex for the duration of study participation and for 4 months following completion of tegavivint administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n\nContraception includes:\n\n* Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\n* Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment\n* Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient\n* Use of oral (estrogen and progesterone), injected or implanted combined hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception\n* Sexually active males must use a condom during intercourse while taking drug and for 4 months after stopping study treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to tegavivint or other agents used in study\n* Known active central nervous system (CNS) lymphoma, history of CNS involvement allowed if in remission for >= 3 months\n* Evidence of chronic active Hepatitis B, chronic active Hepatitis C infection\n* Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy (e.g., strong CYP3A inhibitors and/or concomitant medications that are excluded) are ineligible because of the potential for pharmacokinetic interactions with tegavivint\n* Known history of active TB (Bacillus Tuberculosis)\n* Major surgery within 3 weeks prior to start of study treatment\n* Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality or corrected QT interval (QTc) > 480 msec\n* Uncontrolled concurrent illness including, but not limited to: ongoing or active infection (Viral, bacterial, fungal or other)\n* Psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnant and breastfeeding women are excluded from this study. The effects of tegavivint on the developing human fetus have the potential for teratogenic or abortifacient effects. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with tegavivint\n* Patients with abnormal serum chemistry values other than the specific limits detailed above, that in the opinion of the investigator is considered to be clinically significant, should be discussed with the Study PI before being enrolled in the study\n* Personal history of malignancy except:\n\n  * Cervical intraepithelial neoplasia;\n  * Skin basal cell carcinoma;\n  * Treated localized prostate carcinoma with prostate specific antigen (PSA) <1 ng/mL or untreated indolent prostate cancer\n  * Neoplasia treated with curative intent, in remission for at least three years and considered at low risk of relapse",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Patients must have had at least two prior systemic therapies",
                "criterions": [
                    {
                        "exact_snippets": "at least two prior systemic therapies",
                        "criterion": "number of prior systemic therapies",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "therapies"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "at least two prior systemic therapies",
                        "criterion": "number of prior systemic therapies",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "therapies"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Age >= 18 years",
                "criterions": [
                    {
                        "exact_snippets": "Age >= 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age >= 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "One of the following three conditions:",
                "criterions": [
                    {
                        "exact_snippets": "One of the following three conditions",
                        "criterion": "presence of at least one of three specified conditions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "One of the following three conditions",
                        "criterion": "presence of at least one of three specified conditions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Presence of isolated MYC translocation Or",
                "criterions": [
                    {
                        "exact_snippets": "Presence of isolated MYC translocation",
                        "criterion": "MYC translocation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Presence of isolated MYC translocation",
                        "criterion": "MYC translocation",
                        "requirement": {
                            "requirement_type": "isolation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Presence of isolated MYC translocation",
                        "criterion": "MYC translocation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Presence of isolated MYC translocation",
                        "criterion": "MYC translocation",
                        "requirement": {
                            "requirement_type": "isolation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Creatinine clearance >= 60 ml/min by Cockcroft-Gault (actual body weight will be used to estimate creatinine clearance)",
                "criterions": [
                    {
                        "exact_snippets": "Creatinine clearance >= 60 ml/min by Cockcroft-Gault (actual body weight will be used to estimate creatinine clearance)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "ml/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Creatinine clearance >= 60 ml/min by Cockcroft-Gault (actual body weight will be used to estimate creatinine clearance)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "estimation method",
                            "expected_value": "Cockcroft-Gault using actual body weight"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Creatinine clearance >= 60 ml/min by Cockcroft-Gault (actual body weight will be used to estimate creatinine clearance)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "ml/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Creatinine clearance >= 60 ml/min by Cockcroft-Gault (actual body weight will be used to estimate creatinine clearance)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "estimation method",
                            "expected_value": "Cockcroft-Gault using actual body weight"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients must have radiographically measurable disease by standard positron emission tomography (PET) uptake with at least one site of measured disease by standardized uptake value (SUV)",
                "criterions": [
                    {
                        "exact_snippets": "radiographically measurable disease",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "radiographically measurable disease",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "detection_method",
                            "expected_value": "radiographic"
                        }
                    },
                    {
                        "exact_snippets": "by standard positron emission tomography (PET) uptake",
                        "criterion": "disease detection method",
                        "requirement": {
                            "requirement_type": "method",
                            "expected_value": "standard positron emission tomography (PET) uptake"
                        }
                    },
                    {
                        "exact_snippets": "at least one site of measured disease by standardized uptake value (SUV)",
                        "criterion": "measured disease site by SUV",
                        "requirement": {
                            "requirement_type": "number of sites",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "site"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least one site of measured disease by standardized uptake value (SUV)",
                        "criterion": "measured disease site by SUV",
                        "requirement": {
                            "requirement_type": "measurement method",
                            "expected_value": "standardized uptake value (SUV)"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "radiographically measurable disease",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "radiographically measurable disease",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "detection_method",
                            "expected_value": "radiographic"
                        }
                    },
                    {
                        "exact_snippets": "by standard positron emission tomography (PET) uptake",
                        "criterion": "disease detection method",
                        "requirement": {
                            "requirement_type": "method",
                            "expected_value": "standard positron emission tomography (PET) uptake"
                        }
                    },
                    {
                        "exact_snippets": "at least one site of measured disease by standardized uptake value (SUV)",
                        "criterion": "measured disease site by SUV",
                        "requirement": {
                            "requirement_type": "number of sites",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "site"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least one site of measured disease by standardized uptake value (SUV)",
                        "criterion": "measured disease site by SUV",
                        "requirement": {
                            "requirement_type": "measurement method",
                            "expected_value": "standardized uptake value (SUV)"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients must be willing and able to understand and give written informed consent and comply with all study related procedures",
                "criterions": [
                    {
                        "exact_snippets": "willing and able to understand and give written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willing and able to understand and give written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "comply with all study related procedures",
                        "criterion": "compliance with study procedures",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "willing and able to understand and give written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willing and able to understand and give written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "comply with all study related procedures",
                        "criterion": "compliance with study procedures",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Total bilirubin =< 1.5 x the upper limit of the normal range (ULN)",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin =< 1.5 x the upper limit of the normal range (ULN)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Total bilirubin =< 1.5 x the upper limit of the normal range (ULN)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Histologic transformation of indolent non-Hodgkin's lymphoma (NHL) to DLBCL",
                "criterions": [
                    {
                        "exact_snippets": "Histologic transformation of indolent non-Hodgkin's lymphoma (NHL) to DLBCL",
                        "criterion": "histologic transformation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Histologic transformation of indolent non-Hodgkin's lymphoma (NHL) to DLBCL",
                        "criterion": "histologic transformation",
                        "requirement": {
                            "requirement_type": "from_disease",
                            "expected_value": "indolent non-Hodgkin's lymphoma (NHL)"
                        }
                    },
                    {
                        "exact_snippets": "Histologic transformation of indolent non-Hodgkin's lymphoma (NHL) to DLBCL",
                        "criterion": "histologic transformation",
                        "requirement": {
                            "requirement_type": "to_disease",
                            "expected_value": "DLBCL"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Histologic transformation of indolent non-Hodgkin's lymphoma (NHL) to DLBCL",
                        "criterion": "histologic transformation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Histologic transformation of indolent non-Hodgkin's lymphoma (NHL) to DLBCL",
                        "criterion": "histologic transformation",
                        "requirement": {
                            "requirement_type": "from_disease",
                            "expected_value": "indolent non-Hodgkin's lymphoma (NHL)"
                        }
                    },
                    {
                        "exact_snippets": "Histologic transformation of indolent non-Hodgkin's lymphoma (NHL) to DLBCL",
                        "criterion": "histologic transformation",
                        "requirement": {
                            "requirement_type": "to_disease",
                            "expected_value": "DLBCL"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Contraception includes:",
                "criterions": [
                    {
                        "exact_snippets": "Contraception includes:",
                        "criterion": "contraception",
                        "requirement": {
                            "requirement_type": "inclusion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Contraception includes:",
                        "criterion": "contraception",
                        "requirement": {
                            "requirement_type": "inclusion",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients must be ineligible for or refused autologous or allogenic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy. Prior autologous stem cell transplant and/or CAR-T are allowed, if received >= 3 months prior to enrollment",
                "criterions": [
                    {
                        "exact_snippets": "Patients must be ineligible for or refused autologous or allogenic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy",
                        "criterion": "autologous or allogenic hematopoietic stem cell transplantation or CAR T-cell therapy",
                        "requirement": {
                            "requirement_type": "eligibility/refusal",
                            "expected_value": "ineligible or refused"
                        }
                    },
                    {
                        "exact_snippets": "Prior autologous stem cell transplant and/or CAR-T are allowed, if received >= 3 months prior to enrollment",
                        "criterion": "prior autologous stem cell transplant and/or CAR-T",
                        "requirement": {
                            "requirement_type": "time since therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients must be ineligible for or refused autologous or allogenic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy",
                        "criterion": "autologous or allogenic hematopoietic stem cell transplantation or CAR T-cell therapy",
                        "requirement": {
                            "requirement_type": "eligibility/refusal",
                            "expected_value": "ineligible or refused"
                        }
                    },
                    {
                        "exact_snippets": "Prior autologous stem cell transplant and/or CAR-T are allowed, if received >= 3 months prior to enrollment",
                        "criterion": "prior autologous stem cell transplant and/or CAR-T",
                        "requirement": {
                            "requirement_type": "time since therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Male sterilization (at least 6 months prior to screening). For female patients on the study the vasectomized male partner should be the sole partner for that patient",
                "criterions": [
                    {
                        "exact_snippets": "Male sterilization (at least 6 months prior to screening)",
                        "criterion": "male sterilization",
                        "requirement": {
                            "requirement_type": "procedure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Male sterilization (at least 6 months prior to screening)",
                        "criterion": "male sterilization",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Male sterilization (at least 6 months prior to screening)",
                        "criterion": "male sterilization",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to screening"
                        }
                    },
                    {
                        "exact_snippets": "For female patients on the study the vasectomized male partner should be the sole partner for that patient",
                        "criterion": "vasectomized male partner as sole partner",
                        "requirement": {
                            "requirement_type": "partner exclusivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "For female patients on the study the vasectomized male partner should be the sole partner for that patient",
                        "criterion": "vasectomized male partner as sole partner",
                        "requirement": {
                            "requirement_type": "partner sterilization status",
                            "expected_value": "vasectomized"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Male sterilization (at least 6 months prior to screening)",
                                "criterion": "male sterilization",
                                "requirement": {
                                    "requirement_type": "procedure",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Male sterilization (at least 6 months prior to screening)",
                                "criterion": "male sterilization",
                                "requirement": {
                                    "requirement_type": "time since procedure",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Male sterilization (at least 6 months prior to screening)",
                                "criterion": "male sterilization",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "prior to screening"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "For female patients on the study the vasectomized male partner should be the sole partner for that patient",
                                "criterion": "vasectomized male partner as sole partner",
                                "requirement": {
                                    "requirement_type": "partner exclusivity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "For female patients on the study the vasectomized male partner should be the sole partner for that patient",
                                "criterion": "vasectomized male partner as sole partner",
                                "requirement": {
                                    "requirement_type": "partner sterilization status",
                                    "expected_value": "vasectomized"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x institutional ULN",
                "criterions": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) < 3 x institutional ULN",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alanine aminotransferase (ALT) < 3 x institutional ULN",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x institutional ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) < 3 x institutional ULN",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x institutional ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alanine aminotransferase (ALT) < 3 x institutional ULN",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x institutional ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Increased expression of MYC (>= 40%) and BCL2 (>= 50%) by immunohistochemistry (IHC) or",
                "criterions": [
                    {
                        "exact_snippets": "Increased expression of MYC (>= 40%) by immunohistochemistry (IHC)",
                        "criterion": "MYC expression by IHC",
                        "requirement": {
                            "requirement_type": "expression level",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Increased expression of MYC (>= 40%) by immunohistochemistry (IHC)",
                        "criterion": "MYC expression by IHC",
                        "requirement": {
                            "requirement_type": "detection method",
                            "expected_value": "immunohistochemistry (IHC)"
                        }
                    },
                    {
                        "exact_snippets": "Increased expression of ... BCL2 (>= 50%) by immunohistochemistry (IHC)",
                        "criterion": "BCL2 expression by IHC",
                        "requirement": {
                            "requirement_type": "expression level",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Increased expression of ... BCL2 (>= 50%) by immunohistochemistry (IHC)",
                        "criterion": "BCL2 expression by IHC",
                        "requirement": {
                            "requirement_type": "detection method",
                            "expected_value": "immunohistochemistry (IHC)"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Increased expression of MYC (>= 40%) by immunohistochemistry (IHC)",
                                        "criterion": "MYC expression by IHC",
                                        "requirement": {
                                            "requirement_type": "expression level",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 40,
                                                "unit": "%"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Increased expression of MYC (>= 40%) by immunohistochemistry (IHC)",
                                        "criterion": "MYC expression by IHC",
                                        "requirement": {
                                            "requirement_type": "detection method",
                                            "expected_value": "immunohistochemistry (IHC)"
                                        }
                                    }
                                ]
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Increased expression of ... BCL2 (>= 50%) by immunohistochemistry (IHC)",
                                        "criterion": "BCL2 expression by IHC",
                                        "requirement": {
                                            "requirement_type": "expression level",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 50,
                                                "unit": "%"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Increased expression of ... BCL2 (>= 50%) by immunohistochemistry (IHC)",
                                        "criterion": "BCL2 expression by IHC",
                                        "requirement": {
                                            "requirement_type": "detection method",
                                            "expected_value": "immunohistochemistry (IHC)"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Known history of active TB (Bacillus Tuberculosis)",
                "criterions": [
                    {
                        "exact_snippets": "Known history of active TB (Bacillus Tuberculosis)",
                        "criterion": "active tuberculosis (TB) history",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known history of active TB (Bacillus Tuberculosis)",
                        "criterion": "active tuberculosis (TB) history",
                        "requirement": {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known history of active TB (Bacillus Tuberculosis)",
                        "criterion": "active tuberculosis (TB) history",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known history of active TB (Bacillus Tuberculosis)",
                        "criterion": "active tuberculosis (TB) history",
                        "requirement": {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to tegavivint or other agents used in study",
                "criterions": [
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to tegavivint",
                        "criterion": "allergic reactions to compounds of similar chemical or biologic composition to tegavivint",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of allergic reactions attributed to ... other agents used in study",
                        "criterion": "allergic reactions to other agents used in study",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to tegavivint",
                        "criterion": "allergic reactions to compounds of similar chemical or biologic composition to tegavivint",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of allergic reactions attributed to ... other agents used in study",
                        "criterion": "allergic reactions to other agents used in study",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Psychiatric illness/social situations that would limit compliance with study requirements",
                "criterions": [
                    {
                        "exact_snippets": "Psychiatric illness ... that would limit compliance with study requirements",
                        "criterion": "psychiatric illness",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "social situations that would limit compliance with study requirements",
                        "criterion": "social situations",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Psychiatric illness ... that would limit compliance with study requirements",
                        "criterion": "psychiatric illness",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "social situations that would limit compliance with study requirements",
                        "criterion": "social situations",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy (e.g., strong CYP3A inhibitors and/or concomitant medications that are excluded) are ineligible because of the potential for pharmacokinetic interactions with tegavivint",
                "criterions": [
                    {
                        "exact_snippets": "Human immunodeficiency virus (HIV)-positive",
                        "criterion": "HIV status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "on combination antiretroviral therapy (e.g., strong CYP3A inhibitors and/or concomitant medications that are excluded)",
                        "criterion": "combination antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Human immunodeficiency virus (HIV)-positive",
                        "criterion": "HIV status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "on combination antiretroviral therapy (e.g., strong CYP3A inhibitors and/or concomitant medications that are excluded)",
                        "criterion": "combination antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality or corrected QT interval (QTc) > 480 msec",
                "criterions": [
                    {
                        "exact_snippets": "Clinically significant, uncontrolled heart disease",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant, uncontrolled heart disease",
                        "criterion": "heart disease",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "cardiac repolarization abnormality",
                        "criterion": "cardiac repolarization abnormality",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "corrected QT interval (QTc) > 480 msec",
                        "criterion": "corrected QT interval (QTc)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Clinically significant, uncontrolled heart disease",
                                "criterion": "heart disease",
                                "requirement": {
                                    "requirement_type": "clinical significance",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Clinically significant, uncontrolled heart disease",
                                "criterion": "heart disease",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "uncontrolled"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "cardiac repolarization abnormality",
                        "criterion": "cardiac repolarization abnormality",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "corrected QT interval (QTc) > 480 msec",
                        "criterion": "corrected QT interval (QTc)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Absolute neutrophil count (ANC) ≥ 500/mcL",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) ≥ 500/mcL",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 500,
                                "unit": "mcL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) \u001e 500/mcL",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 500,
                                "unit": "mcL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Platelet count ≥ 25,000/mcL",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count ≥ 25,000/mcL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25000,
                                "unit": "mcL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelet count \u001e 25,000/mcL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25000,
                                "unit": "mcL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Presence of BCL2 translocation with increased expression of MYC (≥40%) with or without MYC translocation",
                "criterions": [
                    {
                        "exact_snippets": "Presence of BCL2 translocation",
                        "criterion": "BCL2 translocation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "increased expression of MYC (≥40%)",
                        "criterion": "MYC expression",
                        "requirement": {
                            "requirement_type": "expression level",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "with or without MYC translocation",
                        "criterion": "MYC translocation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": "with or without"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Presence of BCL2 translocation",
                        "criterion": "BCL2 translocation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "increased expression of MYC (\u001e40%)",
                        "criterion": "MYC expression",
                        "requirement": {
                            "requirement_type": "expression level",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Relapsed/refractory histologically confirmed high-grade B-cell lymphoma (HGBCL) (double hit [DH] and triple hit [TH]) with translocations of MYC and BCL2 and/or BCL6 Or",
                "criterions": [
                    {
                        "exact_snippets": "Relapsed/refractory",
                        "criterion": "disease status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "histologically confirmed high-grade B-cell lymphoma (HGBCL)",
                        "criterion": "high-grade B-cell lymphoma (HGBCL)",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    },
                    {
                        "exact_snippets": "double hit [DH] and triple hit [TH]",
                        "criterion": "lymphoma subtype",
                        "requirement": {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "double hit (DH)",
                                "triple hit (TH)"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "translocations of MYC and BCL2 and/or BCL6",
                        "criterion": "gene translocations",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": [
                                "MYC and BCL2",
                                "MYC and BCL6"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception",
                "criterions": [
                    {
                        "exact_snippets": "Total abstinence (when this is in line with the preferred and usual lifestyle of the patient.",
                        "criterion": "abstinence from sexual activity",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Total abstinence (when this is in line with the preferred and usual lifestyle of the patient.",
                        "criterion": "abstinence from sexual activity",
                        "requirement": {
                            "requirement_type": "consistency with lifestyle",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "excluded methods",
                            "expected_value": [
                                "periodic abstinence",
                                "calendar method",
                                "ovulation method",
                                "symptothermal method",
                                "post-ovulation method",
                                "withdrawal"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Relapsed/refractory histologically confirmed germinal center B-cell-like (GCB) and non-GCB diffuse large B cell lymphoma (DLBCL) with the following features:",
                "criterions": [
                    {
                        "exact_snippets": "Relapsed/refractory",
                        "criterion": "disease status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "histologically confirmed",
                        "criterion": "diagnosis confirmation",
                        "requirement": {
                            "requirement_type": "method",
                            "expected_value": "histology"
                        }
                    },
                    {
                        "exact_snippets": "histologically confirmed",
                        "criterion": "diagnosis confirmation",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "germinal center B-cell-like (GCB) and non-GCB diffuse large B cell lymphoma (DLBCL)",
                        "criterion": "lymphoma subtype",
                        "requirement": {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "germinal center B-cell-like (GCB) DLBCL",
                                "non-GCB DLBCL"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment",
                "criterions": [
                    {
                        "exact_snippets": "Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy)",
                        "criterion": "female sterilization",
                        "requirement": {
                            "requirement_type": "procedure",
                            "expected_value": [
                                "surgical bilateral oophorectomy"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "total hysterectomy",
                        "criterion": "total hysterectomy",
                        "requirement": {
                            "requirement_type": "procedure",
                            "expected_value": "total hysterectomy"
                        }
                    },
                    {
                        "exact_snippets": "tubal ligation at least 6 weeks before taking study treatment",
                        "criterion": "tubal ligation",
                        "requirement": {
                            "requirement_type": "procedure",
                            "expected_value": "tubal ligation"
                        }
                    },
                    {
                        "exact_snippets": "tubal ligation at least 6 weeks before taking study treatment",
                        "criterion": "tubal ligation",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment",
                        "criterion": "reproductive status after oophorectomy alone",
                        "requirement": {
                            "requirement_type": "confirmation by hormone level assessment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Sexually active males must use a condom during intercourse while taking drug and for 4 months after stopping study treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential",
                "criterions": [
                    {
                        "exact_snippets": "Sexually active males must use a condom during intercourse while taking drug and for 4 months after stopping study treatment",
                        "criterion": "condom use by sexually active males",
                        "requirement": {
                            "requirement_type": "use of condom",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Sexually active males must use a condom during intercourse while taking drug and for 4 months after stopping study treatment",
                        "criterion": "condom use by sexually active males",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during study treatment"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "months after stopping study treatment"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Sexually active males ... should not father a child in this period",
                        "criterion": "fathering a child by sexually active males",
                        "requirement": {
                            "requirement_type": "fathering a child",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Sexually active males ... should not father a child in this period",
                        "criterion": "fathering a child by sexually active males",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "during study treatment"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "months after stopping study treatment"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid",
                        "criterion": "condom use by vasectomized men",
                        "requirement": {
                            "requirement_type": "use of condom",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment",
                        "criterion": "stability of oral contraception in women",
                        "requirement": {
                            "requirement_type": "duration of stable use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms)",
                        "criterion": "post-menopausal status in women",
                        "requirement": {
                            "requirement_type": "amenorrhea duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms)",
                        "criterion": "post-menopausal status in women",
                        "requirement": {
                            "requirement_type": "clinical profile",
                            "expected_value": "appropriate (e.g. age appropriate, history of vasomotor symptoms)"
                        }
                    },
                    {
                        "exact_snippets": "Women are considered post-menopausal and not of child bearing potential if they ... have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks ago",
                        "criterion": "surgical sterilization in women",
                        "requirement": {
                            "requirement_type": "procedure",
                            "expected_value": [
                                "bilateral oophorectomy",
                                "tubal ligation"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Women are considered post-menopausal and not of child bearing potential if they ... have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks ago",
                        "criterion": "surgical sterilization in women",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential",
                        "criterion": "confirmation of reproductive status after oophorectomy alone",
                        "requirement": {
                            "requirement_type": "hormone level assessment",
                            "expected_value": "reproductive status confirmed"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Use of oral (estrogen and progesterone), injected or implanted combined hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception",
                "criterions": [
                    {
                        "exact_snippets": "Use of oral (estrogen and progesterone), injected or implanted combined hormonal methods of contraception",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "oral combined hormonal",
                                "injected combined hormonal",
                                "implanted combined hormonal"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "placement of an intrauterine device (IUD) or intrauterine system (IUS)",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "intrauterine device (IUD)",
                                "intrauterine system (IUS)"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "hormone vaginal ring",
                                "transdermal hormone contraception",
                                "other hormonal contraception"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "efficacy",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Women of child-bearing potential (WOCBP) and men who are sexually active with WOCBP must agree to use one hormonal contraceptive (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy or tubal ligation; and one effective method of contraception, including male condom, female condom, cervical cap, diaphragm or contraceptive sponge or abstain from sex for the duration of study participation and for 4 months following completion of tegavivint administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",
                "criterions": [
                    {
                        "exact_snippets": "Women of child-bearing potential (WOCBP)",
                        "criterion": "women of child-bearing potential",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "men who are sexually active with WOCBP",
                        "criterion": "men who are sexually active with women of child-bearing potential",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must agree to use one hormonal contraceptive (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy or tubal ligation; and one effective method of contraception, including male condom, female condom, cervical cap, diaphragm or contraceptive sponge or abstain from sex for the duration of study participation and for 4 months following completion of tegavivint administration.",
                        "criterion": "contraception use or abstinence",
                        "requirement": {
                            "requirement_type": "agreement to contraception or abstinence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must agree to use one hormonal contraceptive (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy or tubal ligation; and one effective method of contraception, including male condom, female condom, cervical cap, diaphragm or contraceptive sponge or abstain from sex for the duration of study participation and for 4 months following completion of tegavivint administration.",
                        "criterion": "contraception use or abstinence",
                        "requirement": {
                            "requirement_type": "contraception methods",
                            "expected_value": [
                                "hormonal contraceptive (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants)",
                                "intrauterine device (IUD)",
                                "intrauterine system (IUS)",
                                "vasectomy",
                                "tubal ligation",
                                "male condom",
                                "female condom",
                                "cervical cap",
                                "diaphragm",
                                "contraceptive sponge",
                                "abstinence"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "must agree to use one hormonal contraceptive (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy or tubal ligation; and one effective method of contraception, including male condom, female condom, cervical cap, diaphragm or contraceptive sponge or abstain from sex for the duration of study participation and for 4 months following completion of tegavivint administration.",
                        "criterion": "contraception use or abstinence",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of study participation"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "months after completion of tegavivint administration"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.",
                        "criterion": "pregnancy during study participation",
                        "requirement": {
                            "requirement_type": "reporting to physician",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Evidence of chronic active Hepatitis B, chronic active Hepatitis C infection",
                "criterions": [
                    {
                        "exact_snippets": "Evidence of chronic active Hepatitis B",
                        "criterion": "chronic active Hepatitis B infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "chronic active Hepatitis C infection",
                        "criterion": "chronic active Hepatitis C infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Major surgery within 3 weeks prior to start of study treatment",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery within 3 weeks prior to start of study treatment",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Personal history of malignancy except:",
                "criterions": [
                    {
                        "exact_snippets": "Personal history of malignancy",
                        "criterion": "personal history of malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Patients with abnormal serum chemistry values other than the specific limits detailed above, that in the opinion of the investigator is considered to be clinically significant, should be discussed with the Study PI before being enrolled in the study",
                "criterions": [
                    {
                        "exact_snippets": "abnormal serum chemistry values other than the specific limits detailed above, that in the opinion of the investigator is considered to be clinically significant",
                        "criterion": "serum chemistry values",
                        "requirement": {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "abnormal serum chemistry values other than the specific limits detailed above, that in the opinion of the investigator is considered to be clinically significant",
                        "criterion": "serum chemistry values",
                        "requirement": {
                            "requirement_type": "clinical significance (per investigator judgment)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "abnormal serum chemistry values other than the specific limits detailed above, that in the opinion of the investigator is considered to be clinically significant",
                        "criterion": "serum chemistry values",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": "other than the specific limits detailed above"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Cervical intraepithelial neoplasia;",
                "criterions": [
                    {
                        "exact_snippets": "Cervical intraepithelial neoplasia",
                        "criterion": "cervical intraepithelial neoplasia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Skin basal cell carcinoma;",
                "criterions": [
                    {
                        "exact_snippets": "Skin basal cell carcinoma",
                        "criterion": "skin basal cell carcinoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Neoplasia treated with curative intent, in remission for at least three years and considered at low risk of relapse",
                "criterions": [
                    {
                        "exact_snippets": "Neoplasia treated with curative intent",
                        "criterion": "neoplasia",
                        "requirement": {
                            "requirement_type": "treatment_intent",
                            "expected_value": "curative"
                        }
                    },
                    {
                        "exact_snippets": "in remission for at least three years",
                        "criterion": "neoplasia remission duration",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "considered at low risk of relapse",
                        "criterion": "risk of neoplasia relapse",
                        "requirement": {
                            "requirement_type": "risk_level",
                            "expected_value": "low"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Uncontrolled concurrent illness including, but not limited to: ongoing or active infection (Viral, bacterial, fungal or other)",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled concurrent illness",
                        "criterion": "concurrent illness",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "ongoing or active infection (Viral, bacterial, fungal or other)",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Treated localized prostate carcinoma with prostate specific antigen (PSA) <1 ng/mL or untreated indolent prostate cancer",
                "criterions": [
                    {
                        "exact_snippets": "Treated localized prostate carcinoma",
                        "criterion": "prostate carcinoma",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "treated"
                        }
                    },
                    {
                        "exact_snippets": "Treated localized prostate carcinoma",
                        "criterion": "prostate carcinoma",
                        "requirement": {
                            "requirement_type": "localization",
                            "expected_value": "localized"
                        }
                    },
                    {
                        "exact_snippets": "prostate specific antigen (PSA) <1 ng/mL",
                        "criterion": "prostate specific antigen (PSA)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "ng/mL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "untreated indolent prostate cancer",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    },
                    {
                        "exact_snippets": "untreated indolent prostate cancer",
                        "criterion": "prostate cancer",
                        "requirement": {
                            "requirement_type": "indolence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Known active central nervous system (CNS) lymphoma, history of CNS involvement allowed if in remission for >= 3 months",
                "criterions": [
                    {
                        "exact_snippets": "Known active central nervous system (CNS) lymphoma",
                        "criterion": "central nervous system (CNS) lymphoma",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "not active"
                        }
                    },
                    {
                        "exact_snippets": "history of CNS involvement allowed if in remission for >= 3 months",
                        "criterion": "history of CNS involvement",
                        "requirement": {
                            "requirement_type": "remission duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Pregnant and breastfeeding women are excluded from this study. The effects of tegavivint on the developing human fetus have the potential for teratogenic or abortifacient effects. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with tegavivint",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant ... are excluded from this study",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding women are excluded from this study",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Pregnant ... are excluded from this study",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnancy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding women are excluded from this study",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}